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Abstract
Background: Elderly patients with non-ST-segment elevation myocardial infarction
(NSTEMI) are rarely included in randomized trials due to concomitant diseases. As a result,
invasive treatment and aggressive pharmacotherapy are used less frequently in this group.
The aim of the study was to analyze the impact of invasive treatment used for elderly patients
(≥ 80 years) with NSTEMI from 2003–2009 and its impact on 24-month outcomes.
Methods: We performed analysis of 13,707 elderly patients, out of 78,422 total NSTEMI
patients, enrolled in the prospective, nationwide, Polish Registry of Acute Coronary Syndromes
(PL-ACS) from 2003 to 2009.
Results: The percentage of elderly NSTEMI population was 17.5%. Invasive treatment
received 24% of them. In-hospital complications (stroke, reinfarction and death) were
significantly less frequent in the invasive group, with the exception of major bleeding, which
occurred almost three times more frequently (2.9% vs. 1.1%, p < 0.0001) in the invasive
group. The 24-month mortality was lower (29.4% vs. 50.4%, p < 0.0001) in the invasive
group and remained so after matching patients by the propensity score method (31.1% vs.
40.9%, p < 0.0001). From 2003 to 2009 the use of thienopyridines, beta-blockers and statins
rose significantly. The frequency of invasive strategy increased significantly, from 10% in to
over 50% in 2009. The frequency of major bleeding increased twofold, however a significant
reduction in the 24-month mortality was observed over the years.
Conclusions: Elderly patients with NSTEMI benefit significantly from invasive strategies
and modern pharmacotherapy recommended by treatment guidelines. Nevertheless, this
approach is associated with an increased incidence of major bleeding. (Cardiol J 2013; 20, 1:
34–43)
Key words: NSTEMI, elderly, percutaneous coronary intervention, mortality,
temporal trends
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Introduction
Nineteen of the twenty countries with the high-
est worldwide percentages of elderly citizens are
European [1]. In 2009, 13% of the Polish popula-
tion was ≥ 65 years of age, and 3.3% were ≥ 80
years of age [2]. In people ≥ 40 years of age, an age
at which there is a real risk of myocardial infarc-
tion (MI), 29% of the Polish population was ≥ 65
years of age, and 7% were ≥ 80 years of age. The
prognosis for the near future foresees further sig-
nificant aging of the Polish population [3]. Ische-
mic heart disease remains the main cause of death
among the elderly and is responsible for approxi-
mately 50% of deaths among people ≥ 80 years of
age [1]. Elderly patients are rarely included in ran-
domized trials due to concomitant diseases and con-
cerns relating to complications, especially bleeding.
As a result, invasive treatment and aggressive phar-
macotherapy are used less frequently in this group
[4, 5], even though it is these high-risk patients that
could potentially benefit the most from modern
treatment methods [6]. Managing ST-segment-
-elevation MI (STEMI) raises fewer questions [7, 8],
as confirmed in the Polish population [9, 10]. Al-
though non-ST-segment-elevation MI (NSTEMI) is
characterized by long-term mortality similar to that
of STEMI [11], the choice of treatment strategies
is usually more challenging. Registries complement
randomized trials and may provide preliminary an-
swers regarding the effectiveness of invasive treat-
ments in elderly MI patients. Therefore, the role
of registries has become essential. Using the data
obtained from the Polish Registry of Acute Coronary
Syndromes (PL-ACS), we analyzed the treatment
methods used for elderly Polish patients (≥ 80) with
NSTEMI from 2004–2009 and their impact on
24-month outcomes.
Methods
We used data from the PL-ACS registry. The
registry’s methodology and an analysis of the first
100,193 patients have been previously described
[12]. In brief, the PL-ACS registry is an ongoing,
nationwide, multicenter, prospective, observation-
al study of consecutively hospitalized Polish pa-
tients due to the entire acute coronary syndrome
(ACS) spectrum. The registry is a joint initiative of
the Silesian Centre for Heart Diseases and the Po-
lish Ministry of Health. The National Health Fund,
a nationwide public health insurance institution in
Poland, provides logistical support. All Polish citi-
zens are required to have a National Health Fund
insurance policy. The pilot phase of the registry
commenced in October 2003 in the Silesia region.
In the following months, all the other regions were
included.
Hospitals were invited to enter the registry if
they had one of the following units: coronary care,
cardiology, cardiac surgery, internal medicine, and
intensive care. They were also invited to join if they
admitted at least 10 ACS patients per year.
A detailed protocol with inclusion and exclu-
sion criteria, methods and logistics, and definitions
of all the fields in the registry dataset was prepared
before the registry was started. The protocol was
revised in May 2005 to be compatible with the Car-
diology Audit and Registration Data Standards
(CARDS) [13]. Nevertheless, the PL-ACS Regis-
try case report form (CRF) covers only part of the
CARDS dataset.
According to the protocol, all admitted patients
with suspected ACS were screened for their eligi-
bility to enter the registry, but they were not en-
rolled until ACS was confirmed. The patients were
then classified as having unstable angina, NSTEMI,
or STEMI. NSTEMI was defined as the presence
of positive cardiac necrosis markers and the ab-
sence of all of the following: ST-segment elevation
≥ 2 mm in contiguous chest leads that is consis-
tent with infarction, ST-segment elevations ≥ 1 mm
in two or more standard leads, and a new left bun-
dle branch block. If the patient was hospitalized in
more than one hospital for the same ACS episode
(i.e., if the patient was transferred), all the hospi-
tals were required to complete the registry data.
These hospitalizations were linked together during
data management and were subsequently analyzed
as a single ACS case.
The data were collected by skilled physicians
who were attending the patients. The data were
entered directly into an electronic CRF or tempo-
rarily printed on a CRF before being transferred to
an electronic CRF. Internal checks for missing or
conflicting data and values markedly outside of their
expected ranges were implemented within the soft-
ware. Further data checking was performed by the
applied data management and analysis center of the
Silesian Centre for Heart Diseases if necessary.
The exact dates of deaths from all causes were
obtained from the official mortality records of the
National Health Fund. The vital status at 24 months
following the NSTEMI was available for all the pa-
tients who were included in the registry up to De-
cember 2009.
The analysis included all the NSTEMI patients
≥ 80 years of age. The clinical characteristics and
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outcomes of the patients treated with invasive (co-
ronary angiography during hospitalization) and con-
servative (no coronary angiography during hospi-
talization) methods were compared. The temporal
trends from 2003–2009 were analyzed for clinical
characteristics, methods of treatment, and early and
long-term outcomes.
Statistical analysis
The continuous variables are expressed as the
mean ± standard deviation (SD) or the median (in-
terquartile range). The significance of their differ-
ences between groups was evaluated using the Stu-
dent’s T-test or the Mann-Whitney test, depend-
ing on the data distribution. The categorical
variables are expressed as percentages; the signi-
ficance of their differences between groups was
evaluated using the c2 test (with Yates’ correction
in cases where the expected value of a cell is < 5).
A propensity score analysis was used to compen-
sate for the nonrandomized design of the study. The
propensity scores were calculated using a multiple
regression model that included all of the covariates
shown in Figure 2. The C-statistic for this model
was 0.84. The 24-month mortalities of the studied
groups and the propensity score-matched sub-
groups were evaluated using Kaplan-Meier analy-
sis and the log-rank test. A multiple-factor Cox pro-
portional hazards regression model was used to
determine the factors affecting the 12-month mor-
tality; the results are shown as relative risks (RR)
and 95% confidence intervals (CI). The significance
of temporal trends over the years in question was
evaluated using the Cochran-Armitage test for cat-
egorical variables and the Jonckheere-Terpstra test
for continuous variables. A two-tailed p value £ 0.05
was considered statistically significant. The calcu-
lations were performed using STATISTICA 10
(StatSoft Inc., Tulsa, OK, USA), MedCalc 11.5
(MedCalc Software, Belgium) and SPSS 17.0 (SPSS
Inc., Chicago, IL, USA).
Results
A total of 78,422 patients were hospitalized due
to NSTEMI in 460 hospitals throughout Poland (in-
cluding 101 (22%) invasive cardiology centers), and
registered in the PL-ACS Registry between Octo-
ber 2003 and December 2009. The percentage of
admissions due to NSTEMI among all the ACS pa-
tients (a total of 244,870 patients) was 32%; this
fraction increased from 20% in 2003 to 38% in 2009
(p for the trend < 0.0001). The percentage of eld-
erly patients (≥ 80 years) with NSTEMI was 17.5%
(n = 13,707); this fraction increased from 12% in
2003 to 18% in 2009 (p for the trend < 0.0001).
Of the 13,707 NSTEMI patients ≥ 80 years of
age, 3,288 (24%) received invasive treatment. The
remaining 10,419 (76%) were treated conservative-
ly. The differences in the baseline clinical charac-
teristics between the patients treated invasively
and those treated conservatively are shown in Ta-
ble 1. The patients treated invasively were young-
er, less frequently female and significantly less fre-
quently admitted with major hemodynamic disor-
ders (pulmonary edema and cardiogenic shock).
Patients with a history of hypertension, hypercho-
lesterolemia, past coronary revascularization, sinus
ECG rhythm and smoking were more frequent in
this group. It is worth noting that invasive treatment
was performed in only 52% the patients admitted
to invasive cardiology wards (n = 5,859), with the
remaining 48% being treated conservatively.
During hospitalization, the patients treated in-
vasively received the drugs recommended by treat-
ment guidelines, such as acetylsalicylic acid,
thienopyridines, statins, beta-blockers and angio-
tensin converting enzyme inhibitors (Table 2), sig-
nificantly more frequently. Heparins, nitrates and
diuretics were used more frequently in patients
treated conservatively. Table 3 shows the treat-
ment details of the invasive group. Percutaneous
coronary interventions (PCI) were performed in
70% of the patients; coronary artery bypass graft-
ing was performed or planned in 13%. After receiv-
ing coronary angiography, almost 20% of patients
were qualified to receive conservative treatment
(without revascularization). Stents were used in
90% of the PCIs, of which 4% were drug-eluting
stents.
The left ventricular ejection fraction (the last
examination while hospitalized) was significantly
higher among the patients treated invasively (Ta-
ble 4). In-hospital complications (stroke, reinfarc-
tion and death) were less frequent in the invasive
group, with the exception of major bleeding, which
occurred almost three times more frequently (2.9%
vs. 1.1%) in the invasive group. The length of hos-
pital stay was three days shorter for the invasive
patients. The 24-month mortality was high, but sig-
nificantly lower (by almost half) in the invasive
group (Fig. 1). After matching patients by the pro-
pensity score method, the prognosis in the invasive
group was still significantly better (Table 5, Fig. 1).
The multivariate analysis controlled for the differ-
ences in baseline characteristics and the pharma-
cotherapy used found that invasive treatment sig-
nificantly decreased 24-month mortality in elderly
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NSTEMI patients (RR 0.67, 95% CI 0.62–0.72,
p < 0.0001) (Fig. 2).
Table 6 presents temporal trends in the clini-
cal characteristics, treatment methods and out-
comes in the elderly NSTEMI patients. The mean
age of the patients did not change over the period
in question, whilst the incidence of diabetes and the
percentage of patients with prior PCI increased sig-
Table 1. The clinical characteristics of the elderly non-ST-segment elevation myocardial infarction pa-
tients, by treatment strategy.
Invasive treatment Conservative treatment P
(n = 3,288)  (n = 10,419)
Age [years]: median (interquartile range) 82 (81–84) 83 (81–86) < 0.0001
Age, range 80–99 80–105 –
Females 52.5% 62.8% < 0.0001
Diabetes mellitus 30.9% 30.5% 0.65
Hypertension 78.6% 71.0% < 0.0001
Hypercholesterolemia 36.3% 32.6% < 0.0001
Current tobacco smoking 22.8% 9.6% < 0.0001
Obesity (body mass index ≥ 30) 14.8% 14.9% 0.84
Prior myocardial infarction 22.9% 22.2% 0.37
Prior percutaneous coronary intervention 5.7% 1.2% < 0.0001
Prior coronary artery bypass grafting 3.2% 1.6% < 0.0001
Cardiac arrest prior to admission 0.7% 1.4% 0.0010
Heart rate on admission 81 ± 20 91 ± 27 < 0.0001
ECG with no ST-T changes 13.0% 16.3% < 0.0001
Heart rhythm other than sinus 15.7% 27.3% < 0.0001
Systolic arterial pressure [mm Hg] 140 ± 27 141 ± 36 0.42
Killip 2 on admission 16.9% 28.0% < 0.0001
Killip 3 on admission 4.5% 13.6% < 0.0001
Killip 4 on admission 1.9% 4.5% < 0.0001
Hospitalization in the invasive ward 100% 27.1% < 0.0001
Table 2. The drugs used during hospitalisation in the elderly non-ST-segment elevation myocardial in-
farction patients, by treatment strategy.
Invasive treatment Conservative treatment P
(n = 3,288) (n = 10,419)
Aspirin 93.5% 89.2% < 0.0001
Thienopyridines 88.2% 41.4% < 0.0001
Glycoprotein IIb/IIIa inhibitors 4.6% 0.1% < 0.0001
Heparins: 58.1% 80.1% < 0.0001
    Low-molecular-weight heparin 37.0% 67.8% < 0.0001
    Unfractionated heparin 27.0% 15.4% < 0.0001
Beta-blockers 80.7% 71.1% < 0.0001
Angiotensin-converting enzyme inhibitors 80.6% 72.3% < 0.0001
Statins 84.9% 69.3% < 0.0001
Calcium antagonists 10.1% 8.9% 0.029
Nitrates 34.5% 59.0% < 0.0001
Fibrates 0.7% 0.6% 0.39
Diuretics 35.9% 55.4% < 0.0001
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nificantly. The incidence of major hemodynamic
disorders on admission (pulmonary edema and car-
diogenic shock) decreased. The use of drugs rec-
ommended by treatment guidelines, such as
thienopyridines, beta-blockers and statins, rose sig-
nificantly. There was a decreasing trend for nitrate
and diuretic use. The frequency of invasive diag-
nostic methods increased significantly, from 10%
in 2003/2004 to over 50% in 2009, which also caused
an increase in the number of percutaneous and sur-
gical revascularization procedures. The length of
hospital stays decreased from 10 days in 2003/2004
to 6 days in 2009. The incidences of in-hospital
stroke, myocardial reinfarction and death de-
creased. The frequency of major bleeding increased
twofold. There was also a significant reduction in
the 24-month mortality over the years.
Table 3. Invasive non-ST-segment elevation myo-
cardial infarction treatments in elderly patients.
Invasive treatment
(n = 3,288)
Multivessel coronary disease 70.0%
PCI: 70.0%
Stent implantation 89.9%
   Drug-eluting stent 3.6%
Multivessel PCI 19.0%
Final TIMI 3 flow after PCI 90.7%
CABG during hospitalization 1.4%
CABG planned after discharge 11.8%
Without revascularization 19.5%
PCI — percutaneous coronary intervention; TIMI — Thrombolysis In
Myocardial Infarction; CABG — coronary artery bypass grafting
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Figure 1. The 24-month mortality by treatment method for all of the elderly non-ST-segment elevation myocardial
infarction patients and for the propensity score matched elderly non-ST-elevation myocardial infarction patients.
Table 4. The in-hospital and long-term prognosis in elderly non-ST-segment elevation myocardial in-
farction patients, by treatment strategy.
Invasive treatment Conservative treatment P
(n = 3,288) (n = 10,419)
Left ventricular ejection fraction 46.3 ± 11.4 44.7 ± 13.5 < 0.0001
Major bleeding 2.9% 1.1% < 0.0001
Stroke 0.4% 1.0% 0.0008
Myocardial reinfarction 1.6% 5.2% < 0.0001
Death 5.0% 14.0% < 0.0001
Length of hospitalization [days]: 6 (3–9) 9 (6–12) < 0.0001
median (interquartile range)
30-day mortality 8.4% 19.5% < 0.0001
6-month mortality 16.2% 32.1% < 0.0001
12-month mortality 21.4% 39.4% < 0.0001
24-month mortality 29.4% 50.4% < 0.0001
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Discussion
This study shows that implementing modern
treatment methods, including invasive strategies
and the pharmacotherapy recommended by treat-
ment guidelines, improves the prognosis of
NSTEMI patients ≥ 80 years of age. However, one
side effect to this treatment approach is an increase
in the incidence of major bleeding complications.
Over the years, an increased frequency of using
both invasive treatments and the drugs recom-
mended by treatment guidelines has been observed.
Despite numerous publications, which are
summarized in the current treatment guidelines of
the European Society of Cardiology [6, 7], our
knowledge of the optimal treatment strategy in eld-
erly NSTEMI patients is still insufficient [5], as eld-
erly patients are rarely included in randomized cli-
Table 5. The in-hospital and long-term prognosis in the propensity score-matched subgroups of elder-
ly non-ST-segment elevation myocardial infarction patients, by treatment strategy.
Invasive treatment Conservative treatment P
(n = 2,362) (n = 2,362)
Major bleeding 2.9% 1.2% < 0.0001
Stroke 0.4% 0.6% 0.41
Myocardial reinfarction 1.8% 4.2% < 0.0001
Death 5.7% 8.5% 0.0002
30-day mortality 9.2% 13.1% < 0.0001
6-month mortality 18.0% 23.9% < 0.0001
12-month mortality 23.2% 30.5% < 0.0001
24-month mortality 31.1% 40.9% < 0.0001
Figure 2. The multivariate analysis of the impact of selected parameters on 24-month mortality in elderly non-ST-
-segment elevation myocardial infarction patients; ACE-I — angiotensin converting enzyme inhibitors; CABG —
coronary artery bypass grafting; GP —  glycoprotein; LVEF — left ventricular ejection fraction; PCI — percutaneous
coronary intervention
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nical trials. Furthermore, they are usually analyzed
together with the unstable angina patients as non-
ST-segment-elevation ACS (NSTE-ACS). The
mean percentage of patients ≥ 75 years of age in
the randomized NSTE-ACS trials from 1994–2000
was approximately 18% [14], whilst the percentage
in clinical registries for that period was 38% [5]. The
percentage of NSTEMI patients ≥ 75 years of age
in the PL-ACS registry is 35%. Furthermore, the
elderly patients included in randomized trials dif-
fer in clinical characteristics from those included in
registries [15], as they are lower risk patients and
consequently have lower 30-day mortalities than
registry patients [5]. This finding is consistent with
our observations. Nevertheless, attention should be
paid to analyzing the subgroups of elderly patients
in those randomized trials where invasive NSTE-
-ACS treatment proved to be more beneficial than
conservative treatment. In the TIMI IIIb (Throm-
bolysis In Myocardial Infarction) trial, the percent-
age of patients ≥ 75 years of age was only 3% [16].
An analysis of the subgroup of patients ≥ 65 years
of age revealed that an early invasive strategy low-
ers the short-term RR of death or MI by 46%; the
statistical significance of this difference remained
for up to one year after the randomization [17]. The
Table 6. The temporal trends in the clinical characteristics, treatment methods and outcomes in elderly
non-ST-segment elevation myocardial infarction patients from 2003–2009.
2003/2004 2005 2006 2007 2008 2009 P for the trend
Age, years (median) 83 83 83 83 83 83 0.34
Female gender 59.9% 59.7% 61.5% 61.7% 59.6% 58.3% 0.25
Diabetes 28.3% 29.6% 28.9% 28.8% 33.0% 35.3% < 0.0001
Prior MI 21.0% 27.4% 21.7% 22.9% 18.2% 21.1% < 0.0001
Prior PCI 0.8% 0.9% 0.8% 1.8% 3.9% 5.8% < 0.0001
Prior CABG 1.7% 2.6% 1.9% 1.6% 1.8% 2.3% 0.60
Killip 3 on admission 12.4% 13.2% 12.6% 11.3% 10.5% 8.0% < 0.0001
Killip 4 on admission 6.5% 4.5% 4.2% 3.3% 3.5% 3.0% < 0.0001
Cardiac arrest prior to admission 1.5% 1.8% 1.0% 1.1% 0.9% 1.4% 0.50
Aspirin 86.9% 91.4% 89.9% 90.3% 90.3% 90.6% 0.39
Thienopyridines 20.2% 28.3% 34.9% 54.5% 79.5% 90.7% < 0.0001
Heparins 72.7% 78.3% 78.9% 77.6% 72.2% 64.4% < 0.0001
GP IIb/IIIa inhibitors 1.4% 0.7% 0.5% 1.2% 1.5% 2.5% < 0.0001
Beta-blockers 62.4% 71.2% 74.5% 75.5% 73.8% 75.1% < 0.0001
Statins 58.5% 69.9% 72.5% 74.4% 76.0% 78.0% < 0.0001
ACE inhibitors 71.3% 74.9% 74.8% 75.7% 74.0% 72.1% 0.29
Nitrates 70.5% 65.5% 59.8% 52.0% 45.5% 30.6% < 0.0001
Diuretics 54.3% 54.5% 52.7% 52.0% 47.5% 43.3% < 0.0001
Invasive treatment 9.8% 13.5% 14.9% 19.3% 33.2% 52.5% < 0.0001
PCI 7.3% 8.7% 10.1% 13.0% 24.6% 37.3% < 0.0001
CABG urgent or delayed 0.9% 3.0% 2.4% 3.3% 4.2% 5.6% < 0.0001
Mean LVEF 44.8% 44.6% 45.3% 45.0% 45.9% 45.8% 0.033
Length of hospitalization, 10 9 8 8 7 6 < 0.0001
days (median)
Stroke 1.2% 1.1% 0.7% 1.0% 0.8% 0.3% 0.0078
Major bleeding 1.6% 0.9% 0.9% 1.1% 2.8% 2.6% < 0.0001
Myocardial reinfarction 5.4% 7.0% 5.6% 3.6% 2.3% 1.6% < 0.0001
Death during hospitalization 15.1% 13.6% 11.9% 11.5% 11.4% 9.2% < 0.0001
30-day mortality 20.9% 17.9% 16.5% 17.1% 16.5% 14.5% 0.0002
6-month mortality 30.9% 29.9% 28.9% 28.6% 27.4% 24.8% < 0.0001
12-month mortality 37.7% 36.7% 35.5% 36.0% 34.5% 31.1% < 0.0001
24-month mortality 47.5% 47.9% 45.2% 46.9% 43.3% 41.6% < 0.0001
MI — myocardial infarction; PCI — percutaneous coronary intervention; CABG — coronary artery bypass grafting; GP — glycoprotein; LVEF — left
ventricular ejection fraction; ACE — angiotensin converting enzyme
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FRISC-II (Fragmin during Instability in Coronary
Artery Disease) trial was the first to demonstrate
the supremacy of invasive strategies over conser-
vative treatment in NSTE-ACS, though no patients
≥ 75 years of age were included in the trial [18]. It
should be mentioned that the patients ≥ 65 years
of age had a significantly higher absolute and rela-
tive reduction in 6-month mortality or MI risk com-
pared to younger age groups, a result that persist-
ed over a 2 years of follow-up [19]. Interestingly,
the subgroup analysis of the TACTICS-TIMI 18
(Treat Angina With Aggrastat and Determine Cost
of Therapy with an Invasive or Conservative Strat-
egy — Thrombolysis in Myocardial Infarction) tri-
al found that over 6 months of follow-up, the patients
who benefited the most from an invasive strategy
were those ≥ 75 years of age [20]. The absolute re-
duction in the 6-month mortality or MI risk in this
age group was 10.8%, whilst the relative reduction
compared to the conservative strategy was as high
as 56%. Furthermore, advanced age was associat-
ed with greater benefit from invasive treatment.
Also, the cost effectiveness of the invasive therapy
increased with age. Nevertheless, a threefold high-
er incidence of major bleedings was observed in the
oldest age group (≥ 75). It should be mentioned that
no significant differences in mortality, reinfarction
or rehospitalization due to unstable angina in the
year following the NSTE-ACS were observed for
the patients in latest ICTUS (Invasive versus Con-
servative Treatment in Unstable Coronary Syn-
dromes) trial, including those aged ≥ 65 [21]. To
sum up randomized trials, it seems that the sub-
group analyses, despite their limitations, demon-
strate the benefits of invasive treatment in elderly
patients with NSTE-ACS, which is consistent with
the results of our analysis.
Registry studies also show the superiority of
invasive treatments over conservative treatment in
elderly NSTE-ACS patients [22, 23]. In a 2002 Ita-
lian registry, the patients ≥ 75 years of age received
treatment consistent with the guidelines less fre-
quently; in the multifactorial analysis, conservative
treatment significantly worsened the 30-days prog-
nosis [22]. The analysis of the GRACE (The Global
Registry of Acute Coronary Syndromes) registry
clearly shows that the patients ≥ 80 years of age,
who made up 16% of the population, received treat-
ment consistent with the guidelines less frequent-
ly. This result applied to both invasive treatment
and pharmacotherapy, which was used half as fre-
quently in those ≥ 80 years of age than in younger
age groups [23]. In the multifactorial analysis, in-
vasive treatment significantly lowered the 6-month
mortality in patients ≥ 80 years of age (odds ratio
0.68, 95% CI 0.49–0.95), a finding which is similar
to our analysis PL-ACS registry. However, the lat-
est analysis of the CRUSADE (Can Rapid Risk
Stratification of Unstable Angina Patients Suppress
Adverse Outcomes With Early Implementation of
ACC/AHA Guidelines) registry did not find de-
creased in-hospital mortality in invasively treated
patients ≥ 75 years of age [24]. It is worth men-
tioning that Li et al. [25] have shown that invasive
treatment for ACS significantly improves quality
of life, with the greatest improvement in patients
≥ 80 years of age.
In our analysis, we observed an increasing
trend in the frequency of using pharmacological and
invasive treatment in elderly patients, which was
reflected in improved in-hospital and 12-month
prognoses. We know from the CRUSADE registry
that the frequency of using drugs recommended by
the treatment guidelines (mainly antiplatelet
agents, anticoagulants and beta-blockers) and the
frequency of invasive treatment is lower in older
patients, especially in the elderly [26]. This finding
was confirmed by an analysis of the GRACE regis-
try in which the percentage of patients ≥ 85 years
of age treated by invasive strategy was only 20%,
as compared to over 50% in younger age groups
[27]. A trend towards more aggressive treatment
of older patients has been observed by Schiele et
al. [28] using a French registry that compared the
year 2000–2001 to the year 2005–2006. The in-
creased frequency of using the recommended phar-
macotherapy and invasive treatments decreased the
35-day mortality only in the STEMI patients; mor-
tality remained stable in NSTEMI patients, and the
incidence of major bleeding increased. However,
the number of patients in the analysis was not large
(n = 868), which undoubtedly affected the statisti-
cal power. An analysis of the trends in a 1996–2006
Canadian study of patients ≥ 80 years of age showed
a significant increase in the frequency of using phar-
macotherapy and invasive treatments recommend-
ed by the guidelines, which resulted in a reduction
in the 12-month mortality [29].
Limitations of the study
There are several limitations of our analysis.
The PL-ACS registry is a prospective observation-
al study and not all hospitals treating ACS in Po-
land participated in data collection. Consequently,
the reported significant trend in reduction of mor-
tality in NSTEMI should be interpreted with cau-
tion. Additionally, the retrospective nature of our
analysis is a potential weakness. Even after data
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adjustment, the results could be biased by poten-
tially important parameters that are not available
in the registry thus, despite using the propensity
score method and the multivariable analysis, the
conclusions require confirmation by a randomized
trial. Finally, as it is a single-country study, it may
be not applicable to populations of the other coun-
tries.
Conclusions
Elderly patients with NSTEMI benefit signifi-
cantly from invasive strategies and modern phar-
macotherapy recommended by treatment guide-
lines. Nevertheless, this approach is associated with
an increased incidence of major bleeding. The lack
of randomized clinical trials that include a represen-
tative group of elderly patients is evident. Hence,
the conclusions of this analysis should be confirmed
by an appropriately designed randomized trial.
Acknowledgments
This manuscript is the result of an unfunded
analysis of the PL-ACS Registry database. How-
ever, the Polish Registry of Acute Coronary Syn-
dromes PL-ACS is supported by an unrestricted
grant from the Polish Ministry of Health. The spon-
sor was not involved in data collection, data man-
agement, and review of the manuscript before sub-
mission, had no role in the design or conduct of this
study, data analysis, interpretation of the data,
manuscript preparation, or approval of the manu-
script.
We thank all the physicians and nurses who
participated in PL-ACS Registry, members of the
Expert Committee, Regional Coordinators, and
people from the National Health Fund of Poland for
their logistic support.
PL-ACS Expert Committee: Lech Poloński
(Chairman), Mariusz Gąsior (Co-Chairman), Marek
Gierlotka (Co-Chairman), Zbigniew Kalarus (Co-
Chairman), Zabrze; Andrzej Cieśliński, Poznań;
Jacek Dubiel, Cracow; Robert Gil, Grzegorz Opols-
ki, Witold Rużyłło, Warsaw; Michał Tendera, Ka-
towice; Marian Zembala, Zabrze.
Contribution of authors: Marek Gierlotka —
conception and design, acquisition of data, analysis
and interpretation of data, drafting the article, final
approval of the version to be published; Mariusz
Gąsior, Mateusz Tajstra, Michał Hawranek, Ta-
deusz Osadnik, Krzysztof Wilczek, Zbigniew
Kalarus, Andrzej Lekston, Marian Zembala — ana-
lysis and interpretation of data, revising the manu-
script critically for important intellectual content,
final approval of the version to be published; Lech
Poloński — conception and design, revising the
manuscript critically for important intellectual con-
tent, final approval of the version to be published.
Conflict of interest: none declared
References
1. Cardiovascular Diseases in Europe. Euro Heart Survey 2006.
Edited by Wilma Scholte et al. http://www.escardio.org/guide-
lines-surveys/ehs/Documents/EHS-CVD-report-2006.pdf.
2. Główny Urząd Statystyczny. http://demografia.stat.gov.pl/Baza-
-Demografia/ Tables.aspx.
3. Główny Urząd Statystyczny. http://www.stat.gov.pl/cps/rde/
/xbcr/gus/PUBL_L_prognoza_ludnosci_Pl_2008-2035.pdf.
4. Gąsior M, Zembala M, Poloński L. Chorzy starsi z ostrym
zespołem wieńcowym: Narastający problem w praktyce klini-
cznej. Kardiol Pol, 2006; 64: 1154–1157.
5. Alexander KP, Newby LK, Cannon CP et al. American Heart
Association Council on Clinical Cardiology; Society of Geriatric
Cardiology. Acute coronary care in the elderly, part I: Non-ST-
-segment-elevation acute coronary syndromes: a scientific state-
ment for healthcare professionals from the American Heart As-
sociation Council on Clinical Cardiology: in collaboration with
the Society of Geriatric Cardiology. Circulation, 2007; 115: 2549–
–2569.
6. Bassand JP, Hamm CW, Ardissino D et al. for the Task Force for
Diagnosis and Treatment of Non-ST-Segment Elevation Acute
Coronary Syndromes of European Society of Cardiology. Guide-
lines for the diagnosis and treatment of non-ST-segment eleva-
tion acute coronary syndromes. Eur Heart J, 2007; 28: 1598–
–1660.
7. Wijns W, Kolh P, Danchin N et al. for The Task Force on Myo-
cardial Revascularization of the European Society of Cardiology
(ESC) and the European Association for Cardio-Thoracic Sur-
gery (EACTS). Guidelines on myocardial revascularization. Eur
Heart J, 2010; 31: 2501–2555.
8. Ciszewski A, Karcz M, Kepka C et al. Primary angioplasty
in patients > or = 75 years old with ST-elevation myocardial
infarction: One-year follow-up results. Kardiol Pol, 2008; 66:
828–833.
9. Polewczyk A, Janion M, Gąsior M, Gierlotka M, Poloński L.
Benefits from revascularisation therapy in the elderly with acute
myocardial infarction. Comparative analysis of patients hospitalised
in 1992–1996 and in 2005–2006. Kardiol Pol, 2010; 68: 873–881.
10. Poloński L, Gąsior M, Gierlotka M et al. A comparison of ST
elevation versus non-ST elevation myocardial infarction out-
comes in a large registry database: Are non-ST myocardial in-
farctions associated with worse long-term prognoses? Int J Car-
diol, 2011; 152: 70–77.
11. Kashima K, Ikeda D, Tanaka H et al. Mid-term mortality of very
elderly patients with acute myocardial infarction with or without
coronary intervention. J Cardiol, 2010; 55: 397–403.
12. Poloński L, Gąsior M, Gierlotka M et al. Polish Registry of Acute
Coronary Syndromes (PL-ACS). Characteristics treatments and
outcomes of patients with acute coronary syndromes in Poland.
Kardiol Pol, 2007; 65: 861–872.
43
Marek Gierlotka et al., Invasive treatment of elderly with NSTEMI
www.cardiologyjournal.org
13. Flynn MR, Barrett C, Cosío FG et al. The Cardiology Audit
and Registration Data Standards (CARDS), European data
standards for clinical cardiology practice. Eur Heart J, 2005;
26: 308–313.
14. Topol EJ, Califf RM, Van de Werf F et al. Perspectives on large-
scale cardiovascular clinical trials for the new millennium: The
Virtual Coordinating Center for Global Collaborative Cardiovascu-
lar Research (VIGOUR) Group. Circulation, 1997; 95: 1072–1082.
15. Kandzari DE, Roe MT, Chen AY et al. Influence of clinical trial
enrollment on the quality of care and outcomes for patients with
non-ST-segment elevation acute coronary syndromes. Am Heart J,
2005; 149: 474–481.
16. The TIMI IIIB Investigators. Effects of tissue plasminogen activa-
tor and a comparison of early invasive and conservative strategies
in unstable angina and non-Q-wave myocardial infarction: Results
from the TIMI IIIB Trial. Circulation, 1994; 89: 1545–1556.
17. Anderson HV, Cannon CP, Stone PH et al. One-year results of
the Thrombolysis In Myocardial Infarction (TIMI) IIIB clinical
trial: a randomized comparison of tissue-type plasminogen acti-
vator versus placebo and early invasive versus early conserva-
tive strategies in unstable angina and non-Q-wave myocardial
infarction. J Am Coll Cardiol, 1995; 26: 1643–1650.
18. FRagmin and Fast Revascularization during InStability in Coro-
nary artery disease (FRISC II) Investigators. Long-term low-
molecular-mass heparin in unstable coronary artery disease:
FRISC II prospective randomised multicentre study. Lancet,
1999; 354: 701–707.
19. Lagerqvist B, Husted S, Kontny F et al. for the Fast Revascula-
rization during In Stability in Coronary artery disease-II Investi-
gators. A long-term perspective on the protective effects of an
early invasive strategy in unstable coronary artery disease: Two-
-year follow-up of the FRISC-II invasive study. J Am Coll Cardiol,
2002; 40: 1902–1914.
20. Bach RG, Cannon CP, Weintraub WS et al. The effect of routine,
early invasive management on outcome for elderly patients with
non-ST-segment elevation acute coronary syndromes. Ann In-
tern Med, 2004; 141: 186–195.
21. de Winter RJ, Windhausen F, Cornel JH et al. for the Invasive
versus Conservative Treatment in Unstable Coronary Syn-
dromes (ICTUS) Investigators. Early invasive versus selective-
ly invasive management for acute coronary syndromes. N Engl
J Med, 2005; 353: 1095–1104.
22. De Servi S, Cavallini C, Dellavalle A et al.; for the ROSAI-2
Investigators. Non-ST-elevation acute coronary syndrome in the
elderly: Treatment strategies and 30-day outcome. Am Heart J,
2004; 147: 830–836.
23. Devlin G, Gore JM, Elliott J et al. for the GRACE Investigators.
Management and 6-month outcomes in elderly and very elderly
patients with high-risk non-ST-elevation acute coronary syn-
dromes: The Global Registry of Acute Coronary Events. Eur
Heart J, 2008; 29: 1275–1282.
24. Bhatt DL, Roe MT, Peterson ED, et al. for the CRUSADE In-
vestigators. Utilization of early invasive management strategies
for high-risk patients with non-ST-segment elevation acute cor-
onary syndromes: Results from the CRUSADE Quality Improve-
ment Initiative. JAMA, 2004; 292: 2096–2104.
25. Li R, Yan BP, Dong M et al. Quality of life after percutaneous
coronary intervention in the elderly with acute coronary syn-
drome. Int J Cardiol, 2010; 155: 90–96.
26. Alexander KP, Roe MT, Chen AY et al. for the CRUSADE In-
vestigators. Evolution in cardiovascular care for elderly patients
with non-ST-segment elevation acute coronary syndromes: Re-
sults from the CRUSADE National Quality Improvement Initia-
tive. J Am Coll Cardiol, 2005; 46: 1479–1487.
27. Avezum A, Makdisse M, Spencer F et al. for the GRACE Inves-
tigators. Impact of age on management and outcome of acute
coronary syndrome: Observations from the Global Registry of
Acute Coronary Events (GRACE). Am Heart J, 2005; 149: 67–73.
28. Schiele F, Meneveau N, Seronde MF et al. Changes in manage-
ment of elderly patients with myocardial infarction. Eur Heart J,
2009; 30: 987–994.
29. Pagé M, Doucet M, Eisenberg MJ, Behlouli H, Pilote L. Temporal
trends in revascularization and outcomes after acute myocardial
infarction among the very elderly. CMAJ, 2010; 182: 1415–1420.
